Vaccines:
Indications for: SHINGRIX
Prevention of herpes zoster (shingles): in adults ≥50yrs of age; or in adults ≥18yrs of age at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy.
Limitations of Use:
Not for preventing primary varicella infection (chickenpox).
Adult Dosage:
Give by IM inj in deltoid region of upper arm. ≥50yrs: one 0.5mL dose at Month 0 followed by second dose given between 2–6 months later. Immunocompromised (≥18yrs): one 0.5mL dose at Month 0 followed by second dose given between 1–2 months later.
Children Dosage:
<18yrs: not established.
SHINGRIX Contraindications:
Allergies to any previous Shingrix vaccination.
SHINGRIX Warnings/Precautions:
Review immunization history prior to administration. Have appropriate medical treatment and supervision available to manage allergic reactions. Syncope. Pregnancy. Nursing mothers.
SHINGRIX Classification:
Shingles vaccine.
SHINGRIX Interactions:
Concomitant influenza vaccines: see full labeling.
Adverse Reactions:
Local reactions (eg, pain, redness, swelling), myalgia, fatigue, headache, shivering, fever, GI symptoms; Guillain-Barre syndrome, transient neurological effects.
Note:
To report adverse events, contact VAERS at (800) 822-7967.
Generic Drug Availability:
NO
How Supplied:
Single-dose vials—1, 10 (antigen + adjuvant components)
